Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 9/20 | 0.46 |
| ▸ | SLC5A1 | P13866 | 6/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15682904 | 1.00 | SLC5A2 (0.46) | SLC5A2SLC5A1ADAMTS4MMP13SYK | |
| SCHEMBL14949125 | 1.00 | SLC5A2 (0.46) | SLC5A2SLC5A1ADAMTS4MMP13SYK | |
| SCHEMBL14949150 | 0.88 | SLC5A2 (0.59) | SLC5A2SLC5A1HRH3 | |
| SCHEMBL17859644 | 0.88 | SLC5A2 (0.59) | SLC5A2SLC5A1HRH3 | |
| SCHEMBL15681530 | 0.86 | SLC5A2 (0.43) | SLC5A2SLC5A1ACACBFFAR1PDE4D | |
| SCHEMBL19019428 | 0.80 | SLC5A2 (0.44) | SLC5A2SLC5A1PDE4D | |
| SCHEMBL19019426 | 0.80 | SLC5A2 (0.44) | SLC5A2SLC5A1PDE4D | |
| SCHEMBL7760091 | 0.79 | LRRK2 (0.43) | SYKACACBHRH3 | |
| SCHEMBL21443397 | 0.79 | LRRK2 (0.43) | SYKACACBHRH3 | |
| SCHEMBL13993826 | 0.79 | LRRK2 (0.43) | SYKACACBHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776449-B1 | PROCESS FOR THE PREPARATION OF BETA-C-ARYL GLUCOSIDES | SCINOPHARM TAIWAN LTD (TW) | 2017-08-02 | — | — | EP | disclosed |
| US-8952139-B2 | Process for the preparation of β-C-aryl glucosides | SCINOPHARM TAIWAN, LTD (TW) | 2015-02-10 | — | — | US | disclosed |
| US-20140128595-A1 | Process for the Preparation of ß-C-Aryl Glucosides | SCINOPHARM TAIWAN, LTD. (TW) | 2014-05-08 | — | — | US | disclosed |
| WO-2013068850-A2 | PROCESS FOR THE PREPARATION OF β-C-ARYL GLUCOSIDES | SCINOPHARM TAIWAN, LTD. (NA) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128595-A1 | Process for the Preparation of ß-C-Aryl Glucosides | SLC5A2, SLC5A1, UGGT1 | SLC5A2 1/4885SLC5A1 2/4885ADAMTS4 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.